$歌礼製薬(01672.HK)$announced in partnership with Sagimet Biosciences Inc. The first patient in its Phase IIb non-alcoholic steatohepatitis (NASH) clinical trial (fascinate-2) has been administered.
1
1
報告
cheez_lit :
great to see that medicine in the world continues to improve
歌礼製薬に関するコメント
it will go much higher!
まだコメントはありません